Try our Advanced Search for more refined results

February 02, 2018

In re: Onglyza (Saxagliptin) and Kombiglyze (Saxagliptin and Metformin) Products Liability Litigation MDL 2809

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. August 02, 2022

    AstraZeneca, Bristol Myers, McKesson Snag Early Win In MDL

    A Kentucky federal judge on Tuesday handed AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb Co. and McKesson Corp. an early win in multidistrict litigation over their diabetes drugs Onglyza and Kombiglyze, ruling that the plaintiffs haven't offered admissible expert testimony that the medicines can cause heart failure.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!